Begin from the original form of torture and become immortal

Chapter 1424 Promote
But Bronski soon put these thoughts behind him, because he firmly believed that as long as the day came when Hydra no longer hid, he would become one of the key figures in Hydra's rule over the world.

……

In the vast universe of biotechnology and genetic engineering, Osborne Industries is like a shining star, leading the transformation of the global biological and medical industries with its outstanding R&D capabilities and forward-looking technological vision.

Just as Stark Industries once dominated the field of weapons manufacturing, Osborn Group has become a benchmark in the global biomedical industry with its deep accumulation in the field of biotechnology.

Professor Connors, Professor of Biology and Medicine, is standing in the heart of the Osborne Industrial Biolaboratory, where his cross-species gene transplantation project aims to treat or prevent a range of genetic diseases by extracting beneficial genes from other species and transplanting them safely and effectively into humans.

This project not only carries Osborn Industries' expectations for the future medical revolution, but is also Norman Osborn's only hope to save his family's fate.

Norman Osborn, the head of Osborn Industries, is an entrepreneur who seems to be very successful in the eyes of the outside world. However, he is actually suffering from a genetic disease called "retroviral hyperplasia".

This disease, with its unique inheritance pattern, causes the Norman family's descendants to develop the disease earlier and earlier in generation, as if it were a curse, silently devouring the lives of family members.

Through sophisticated genetic research, Norman discovered that his age of onset was much earlier than his father's. What was even more distressing was that by analyzing his son Harry Osborn's blood sample, he predicted that Harry's onset would be even more urgent, and he might not even live past his thirties.

Faced with this cruel reality, Norman's expectations for the cross-species gene transplantation project have reached an unprecedented high.

He believes that only through this technology can he break the family's genetic shackles and win hope of survival for future generations.

However, the road of scientific exploration is never smooth, and Professor Connors' project is facing unprecedented challenges.

The decay rate algorithm, a seemingly simple but actually complex mathematical model, is the key to the success of cross-species gene transplantation.

It requires precise calculation of the stability, expression efficiency and potential side effects of xenogeneic genes in the human body to ensure that the transplanted genes can play a long-term and stable role in the human body without triggering an immune response or causing other unknown health problems.

However, it was this crucial algorithm that became the biggest stumbling block in Professor Connors' research.

In order to overcome this problem, Osborne Industries invested a lot of manpower, material and financial resources, but progress was still slow.

Professor Connors and his team tried a variety of algorithm models, from traditional statistical methods to advanced machine learning algorithms, but they have never been able to find a solution that can accurately predict gene decay rates while taking into account safety and effectiveness.

At the same time, they are faced with another major challenge in the development of new drugs - how to pass the strict review of the FDA and promote cross-species gene transplantation technology from the laboratory to clinical application.

In the United States, any new drug or medical technology involving human trials must undergo strict review by the Food and Drug Administration (FDA), including assessments of safety, effectiveness, ethics, and other aspects.

Especially for high-risk areas such as cross-species gene transplantation involving the implantation of xenogeneic genes, the FDA's review standards are particularly strict, usually taking up to a decade and investing hundreds of millions of dollars.

Professor Connors knew that even if they eventually succeeded in developing a decay rate algorithm, it would only be the first step in a long journey.

Next, they will also need to face the problem of how to apply for IND (new drug clinical research application), how to conduct human trials under the premise of strictly following ethical principles, and how to collect sufficient data to prove the safety and effectiveness of the drug during the long clinical trial process.

Just now, Professor Connors tried again in the laboratory to transplant the gene fragments of reptiles into mice, hoping to use the regenerative ability contained in these genes to repair the damaged limbs of mice. However, the results of the experiment once again shattered his hopes.

Not only did the mouse's wound fail to heal as expected, but it quickly became red and swollen, producing a strong rejection reaction. This is one of the problems that current gene editing technology cannot overcome.

Professor Connors watched the little white mouse struggling in pain, his heart filled with helplessness and self-blame.

Scientific progress is always accompanied by failures and setbacks, but every failure is like another blow to his confidence.

Gene transplantation is not just a simple “cut-and-paste” process, but also requires consideration of multiple complex factors such as the regulation of gene expression, host cell compatibility, and potential immune rejection reactions.

Although he has made countless optimizations and adjustments, it is clear that the current technical framework is not enough to support him in achieving this grand goal.

Chang Wei is planning to speed up the birth of Dr. Lizard in order to enhance the strength of Hydra.

In this world, Hydra has already recruited two well-known villains, but Chang Wei thinks this is not enough because he needs enough villains to fight against the upcoming forces of justice.

And Dr. Lizard, a villain with regenerative abilities and great strength, who can even fight Spider-Man in hand-to-hand combat, is undoubtedly an ideal choice.

"From the looks of it now, it should be The Amazing Spider-Man?"

Chang Wei thought.

In the MCU movie universe, Spider-Man is portrayed as Little Spider, the youngest Spider-Man, but the existence of Professor Connors makes this setting confusing.

If Professor Connors really exists in this world, it may mean that The Amazing Spider-Man will also appear, and even classic villains like the Green Goblin may be born.

"Green Goblin Serum, that's a good thing that's even more powerful than Spider-Man in hand-to-hand combat."

The Green Goblin Serum, a biological agent that grants its user super strength and speed, has effects so powerful that even Spider-Man has difficulty matching it.

For Chang Wei, such power is undoubtedly an excellent way to enhance the strength of Hydra.

"Who?"

Professor Connors panicked.

He had just stood up from the microscope, ready to record the latest experimental observation data, but unexpectedly captured Chang Wei's undisguised voice, a tone mixed with curiosity and frivolity, which obviously did not belong to this usually silent space where only scientific rigor was allowed to exist.

Professor Connors' heartbeat accelerated involuntarily, and he looked around quickly, trying to find the source of the sound.

(End of this chapter)